Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
1(6%)
Results Posted
43%(6 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_2
4
24%
Ph phase_3
5
29%
Ph phase_4
2
12%
Ph not_applicable
1
6%

Phase Distribution

0

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
4(33.3%)
Phase 3Large-scale testing
5(41.7%)
Phase 4Post-market surveillance
2(16.7%)
N/ANon-phased studies
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

17

all time

Status Distribution
Active(1)
Completed(14)
Terminated(2)

Detailed Status

Completed14
Withdrawn1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
1
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (33.3%)
Phase 35 (41.7%)
Phase 42 (16.7%)
N/A1 (8.3%)

Trials by Status

withdrawn16%
terminated16%
completed1482%
recruiting16%

Recent Activity

Clinical Trials (17)

Showing 17 of 17 trials
NCT06710184Phase 4

Treatment With Aspirin Alone Versus Aspirin in Combination With Fondaparinux Before Early Coronary Assessment in Patients With Non-ST-Elevation Myocardial Infarction

Recruiting
NCT05001776Phase 4

Endovenous Laser Ablation in Acute Thrombophlebitis of the Varicose Great Saphenous Vein

Completed
NCT00381888Phase 2

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Completed
NCT00256100Not Applicable

Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.

Terminated
NCT00981409Phase 3

The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed
NCT00911157Phase 3

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients

Completed
NCT00038961Phase 3

A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).

Completed
NCT00843492Phase 3

A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery

Completed
NCT01428544

Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)

Completed
NCT01428531

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Completed
NCT01064362

Hemorrhage Risk Prescribed Arixtra

Completed
NCT01390883

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)

Completed
NCT01390896

Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery

Completed
NCT00531843Phase 2

The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients

Completed
NCT00060554Phase 2

A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Withdrawn
NCT00333021Phase 3

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

Completed
NCT00436787Phase 2

Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17